Medtronic Receives CE Mark For Endeavor

EHM News Bureau - Mumbai

Medtronic, India recently received CE Mark (Conformité Européenne) approval for the commercial sale of the Endeavor Drug-Eluting Coronary Stent with the Rapid Exchange Delivery System in India. The Endeavor system is the first cobalt alloy platform on the drug-eluting stent (DES) market.

“We are very pleased to provide physicians and patients with Medtronic’s high performance Endeavor DES system,” said Milind Shah, MD Medtronic India. “Physicians will now have a broader choice among the DES stents that are available to treat their patients. We believe the Endeavor system offers a powerful combination of deliverability, efficacy and safety that is unmatched by any other commercially available stent.” He further added that Medtronic sales representatives and customer support staffs are trained, and the company has an ample supply of Endeavor systems to support an aggressive rollout.“ Dr Jean Fajadet, MD, Clinique Pasteur Unité de Cardiologie Interventionnelle, Toulouse, France, and one of the co-principal investigators of the ENDEAVOR II pivotal trial, said, “The results from the ENDEAVOR trials to date have been both comprehensive and positive,” said Dr Fajadet.